Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | PTDSS1 | P48651 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4359022 | 0.85 | CYP19A1 (0.41) | CYP19A1ESR1ESR2MGLL | |
| SCHEMBL4366657 | 0.82 | ESR1 (0.51) | ESR1ESR2 | |
| SCHEMBL6205761 | 0.81 | KDM4E (0.46) | CYP19A1KMT2A | |
| SCHEMBL4370441 | 0.81 | AR (0.55) | CYP19A1ESR2MAPT | |
| Hydrochloric Acid SCHEMBL4361996 | 0.80 | KDM4E (0.45) | CYP19A1KMT2A | |
| SCHEMBL4362107 | 0.79 | FFAR1 (0.42) | CYP19A1ESR1ESR2 | |
| SCHEMBL4359940 | 0.78 | CYP19A1 (0.49) | CYP19A1MAPTKMT2A | |
| SCHEMBL4375482 | 0.77 | HSPB1 (0.43) | PPARGMAPTKMT2A | |
| SCHEMBL4951613 | 0.77 | KDM4E (0.55) | CYP19A1KMT2A | |
| SCHEMBL4362360 | 0.77 | CA2 (0.46) | CYP19A1ESR1ESR2KCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482340-B2 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2009-01-27 | — | — | US | disclosed |
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | SLC8B1, CACNA1A, MCU | CYP19A1 2119/4885FAAH 2989/4885PTDSS1 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.